Table 2.

Summary of patient outcomes

Patient no.	Sex/ age	Number of G47∆ doses	Time to progression (d)a	Best response	OS (d)		Treatment after progression	Outcome	Autopsy	Cause of death
					After initial surgery	After 1st G47Δ therapy
1	M/54	6	258	SD	863	485	Bevacizumab after reoperation (GTR)	Dead	+	Tumor progression
2	M/49	6	588	SD	1,748	1,657	Extended field SRS	Dead	+	Tumor progression
3	F/63	6	762b	SD	1,044	941	−	Dead	−	Tumor progression
4	M/69	5	115	SD	891	626	Bevacizumab	Dead	−	Tumor progression
5	M/46	6	133	SD	1,310	882	Bevacizumab after reoperation (GTR) Nimustine	Dead	+	Tumor progression
6	F/25	3	43	SD	897	181	Bevacizumab	Dead	−	Tumor progression
7	M/51	2	64	SD	489	398	Bevacizumab	Dead	−	Tumor progression
8	M/73	6	294	SD	817	655	Extended field SRS; bevacizumab	Dead	−	Tumor progression
9	M/46	6	1,696b	SD	2,716c	1,960c	−	Stable	NA	NA
10	M/28	4	79	SD	1,452	1,166	Extended field SRS	Dead	−	Tumor progression
11	M/53	6	1,584b	SD	2,073c	1,848c	−	Stable	NA	NA
12	M/59	6	139	SD	596	469	Bevacizumab	Dead	−	Tumor progression
13	F/53	6	573b	SD	709	583	−	Dead	+	Not related to the disease
14	M/42	4	78	SD	543	236	Bevacizumab	Dead	−	Tumor progression
15	M/65	6	142	SD	569	434	Bevacizumab	Dead	−	Tumor progression
16	M/45	6	163	SD	699	606	Extended field SRS; bevacizumab	Dead	+	Tumor progression
17	M/68	2	127	PR	1,554c	1,435c	Bevacizumab after reoperation (partial resection)	Stable	NA	NA
18	F/43	5	108	SD	244	127	−	Dead	−	Tumor progression
19	M/35	6	331	SD	667	556	Bevacizumab; spinal irradiation	Dead	−	Tumor progression

Abbreviations: F, female; M, male; PR, partial response; SD, stable disease; GTR, gross total resection; SRS, stereotactic radiosurgery (radiotherapy).

^aIncluding the date of first administration.

^bTumor progression occurred after initial cut-off date for judgment of outcome.

^cPatient remained alive at most recent observation date (1 March 2022) used to analyze survival.

Extent of tumor resection at reoperation: GTR is defined as >95% of the tumor removed assessed by the surgeon.